Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 7,180,206 $ 4,401,114
Prepaid research and development 235,535 233,035
Prepaid expenses and other current assets 569,784 501,689
Total Current Assets 7,985,525 5,135,838
Other Assets:    
Research and development supplies 1,548,397
Right-to-use asset 258,594
Acquired in-process research and development 455,000
Goodwill 131,495
Fixed assets, net 62,012
Advance to seller 350,000
Intangible assets, net 5,183 5,606
Total Assets 10,446,206 5,491,444
Current Liabilities:    
Accounts payable and other current liabilities 185,187 648,739
Accrued expenses 1,724,839 856,639
Lease liability, current 47,819
Total Current Liabilities 1,957,845 1,505,378
Lease liability, net of current portion 220,249
Contingent liabilities 1,068,014
Total Liabilities 3,246,108 1,505,378
Commitments and contingencies
Shareholders’ Equity    
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at September 30, 2021 and December 31, 2020
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 20,448,156 and 14,393,100 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 20,448 14,393
Additional paid in capital 52,291,921 35,491,462
Accumulated deficit (45,112,271) (31,519,789)
Total Shareholders’ Equity 7,200,098 3,986,066
Total Liabilities and Shareholders’ Equity $ 10,446,206 $ 5,491,444